In an SEC Filing, it was disclosed that Carl Icahn has taken a larger stake as an activist in Enzon Pharmaceuticals Inc. (NASDAQ: ENZN). The stake is listed as 6.93% for just over 3.07 million shares.
Icahn Capital was already a holder as of last year. Icahn is suggesting disappointment over the price of the company and he has suggested strategic alternatives including a sale of the company. The group has held talks with management and plans to seek further discussions.
Enzon shares were in negative territory for the day, but now shares are up almost 5% at $8.90. The 52-week trading range is $6.31 to $10.36.
This is via entities such as High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P. (NYSE: IEP), Icahn Enterprises G.P. Inc., Beckton Corp., and Carl C. Icahn himself.
Jon C. Ogg
March 14, 2008
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
